GBT Tokenize Commencing Open Public Research in Kirlian Electrophotography Technique

SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) — GBT Technologies Inc. (OTC PINK: GTCH) (“GBT”, or the “Company”), announced that GBT Tokenize (“GBT/Tokenize”) started research in the Kirlian Electrophotography imaging technique potentially aimed for inclusion within its qTerm device. GBT/Tokenize’s qTerm, is a human vitals device powered by AI and is aimed to measure human vitals with a touch of a finger. 

GBT/Tokenize encourages public participation in its research. Scientists and researchers that are interested to participate in our research are welcome to send us their material for evaluation at [email protected]

The human body emits various radiations such as infrared, electromagnetic radiation, low level visible light and ultraviolet radiation. This human biofield carries unique information which can potentially be useful for diagnosing and predicting diseases. The various aspects of this biofield can be measured in order to identify organ and/or tissue dysfunctions and therefore potentially detect early stages of possible diseases. Early detection is essential to ensure proper treatment and care.

Kirlian Electrophotography technique is a photographic method to capture the phenomenon of electrical coronal discharges which can be used to produce a human’s organ biofield. The technique is based on shooting a high voltage charge through an object that is connected to a photographic plate. The resulting image typically includes a colored aura around the object. When performed on a human organ the aura is its biofield. The research will be focusing on using Kirlian imaging techniques for early disease diagnostics. GBT/Tokenize’s Machine Learning system is aimed to analyze the biofield data and possible detection of onset disease. Based on Kirlian images and patterns, GBT/Tokenize’s AI seeks to observe, study, analyze and ultimately alert physicians about possible underlying illnesses or symptoms. If developed and commercialized, such a system can be efficient for remote telemedicine diagnostics and medical advice.

“We are excited to start new research for our qTerm device” stated Danny Rittman, GBT’s CTO. “This research is about the analysis of Kirlian electrophotography data in order to detect an onset of possible illnesses. Kirlian imaging can produce a bio-energy of human’s organs and can perform as a diagnostic tool. Using Kirlian imaging, we believe it is possible to produce a measure of human energy levels and examine changes in the energy distribution throughout the organ(s). We are attempting to determine if we can implement Kirlian imaging for qTerm by means of producing a human’s finger aura (i.e. its biofield). Along with qTerm vitals measurement, the goal is to potentially provide a Kirilian image. In turn, using our Machine learning technology, we are seeking to develop an analysis of the biofield and, in turn, provide a diagnostic and potential medical issues classification. We believe this type of system, if fully developed and commercialized, could be very efficient as additional diagnostic system. We commenced our research and we encourage public participation in this research and we will share our findings on our website qterm.me” continued Dr. Rittman.

Illustration of Kirlian photograph of a fingertip, 1989:

https://www.globenewswire.com/NewsRoom/AttachmentNg/c55add1f-ab66-46c8-a221-7abc238bebea

Actual Test imaging (for presentation purposes only):

https://www.globenewswire.com/NewsRoom/AttachmentNg/4107d872-4784-4d8f-87ff-e294f4127476

Forward-Looking Statements

Certain statements contained in this press release may constitute “forward-looking statements”. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of the press release.

Contact:

Dr. Danny Rittman, CTO
GBT Technologies Inc.
Media: [email protected]

All-New Styleisure™ Brand at JCPenney Promotes Equal Parts Style and Comfort as Company Continues to Innovate Ahead of the Holiday Season

All-New Styleisure™ Brand at JCPenney Promotes Equal Parts Style and Comfort as Company Continues to Innovate Ahead of the Holiday Season

Styleisure™ apparel line is designed to comfortably elevate your everyday

Launching Stylus™ women’s apparel brand Nov. 12 with size-inclusive assortment

PLANO, Texas–(BUSINESS WIRE)–
JCPenney today announced an additional installment of their New and Wow! brands with the introduction of Stylus™ apparel brand. This brand is part of an all-new styleisure™ apparel line which is designed to comfortably elevate your everyday. Only at JCPenney, the Stylus brand is the leader in this new fashion mindset that enables customers to dress effortlessly with both comfort and style. Not to be confused with athleisure, our Stylus brand provides the style and comfort our customers are craving in their multifaceted daily lives, creating a solution that reaches beyond the activewear category.

The Stylus brand’s all-day comfort plus style versatility reflects how JCPenney customers live, whether working from home or in the office, shopping, preparing for the holiday season, or virtually getting together with friends and family. The sophisticated combination of fabric and design, woven into a variety of pieces – including cardigans, easy pants, jumpsuits and tees – can be mixed and matched to seamlessly transition for whatever the day or night may bring. Importantly, the Stylus brand doesn’t ask shoppers to sacrifice fashion for comfort, or vice versa, as ultra-soft fabrics offer unrestricted movement and a relaxed fit. Modern color palettes are paired together based on thoughtfully designed details – including tapered legs, curved hems, and twist-front tops. The Stylus brand allows our customers to be comfortable and look and feel put together to elevate their every day.

“We are excited to launch the Stylus brand right now and in time for the 2020 holiday season for our customers – including our All-In Shopping Enthusiast – who are looking for comfortable yet stylish pieces that fit all aspects of their lives,” said Michelle Wlazlo, EVP, chief merchandising officer. “We began developing the concept of our styleisure™ line, which is exclusive to JCPenney, nearly a year ago to fill this unmet need as customers dress for their day. The Stylus collection is a curated array of neutrals that make it easy to layer and swap pieces for a virtually endless combination of looks, representing true modern comfort and style.”

“Everything we do is with our customers at the forefront – we want our customers to feel and know they’re represented,” Wlazlo continued. “Our inclusive sizing is a philosophy, not an afterthought. Size should never be a deterrent to style or the ability to feel empowered, confident, and comfortable.”

The Stylus brand size assortment ranges from XS to 3X, with consistent pricing from $26 to $89 across all sizes. The introduction of the Stylus brand follows the repositioning and launch of several exclusive JCPenney brands in 2020, including a.n.a a new approach® and Linden Street™, which are offered alongside a wide array of national brands including Nike®, adidas®, Champion®, Levi’s®, Puma®, Clarks®, Cuisinart®, Sharper Image®, Disney®, Lego®, Mattel® and more.

As JCPenney continues implementing its Plan for Renewal transformation strategy, the Stylus brand is a true testament to the Company’s continuous innovative commitment to offer compelling merchandise for today’s shoppers. The brand is now available in 363 stores nationwide and on the JCPenney app and flagship store, jcp.com, offering inclusive sizing and can’t-miss value.

About JCPenney

J. C. Penney Company, Inc. (OTCMKTS: JCPNQ), one of the nation’s largest apparel and home retailers, combines an expansive footprint of stores across the United States and Puerto Rico with a powerful eCommerce site, jcp.com, to deliver style and value for all hard-working American families. At every touchpoint, customers will discover stylish merchandise at incredible value from an extensive portfolio of private, exclusive and national brands. Reinforcing this shopping experience is the customer service and warrior spirit of JCPenney associates across the globe, all driving toward the Company’s mission to help customers find what they love for less time, money, and effort. For additional information, please visit jcp.com.

JCPenney Corporate Communications and Public Relations:

Kristen Bennett

(972) 431-3400 or [email protected]

Follow @jcpnews on Twitter for the latest announcements and Company information.

Investor Relations:

(972) 431-5500 or [email protected]

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Other Retail Specialty Online Retail Consumer Fashion Other Consumer Retail Department Stores

MEDIA:

Logo
Logo

New York City REIT Announces Third Quarter 2020 Results

New York City REIT Announces Third Quarter 2020 Results

NEW YORK–(BUSINESS WIRE)–
New York City REIT, Inc. (NYSE: NYC) (“NYC” or the “Company”), a real estate investment trust that owns a portfolio of high-quality commercial real estate located within the five boroughs of New York City, announced today its financial and operating results for the third quarter ended September 30, 2020.

Third Quarter 2020 and Subsequent Event Highlights

  • Revenue was $17.0 million as compared to $18.6 million for the third quarter 2019
  • Net loss attributable to common stockholders was $12.3 million as compared to $4.8 million for the third quarter 2019
  • Cash net operating income (“NOI”) was $6.1 million compared to $8.8 million for the third quarter 2019
  • Funds from Operations (“FFO”) of $(3.6) million, compared to $3.0 million for the third quarter 2019
  • Core Funds from Operations (“Core FFO”) of $0.5 million compared to $3.0 million in the prior year third quarter
  • Collected 85% of cash rent due in third quarter 20201, including 85% among the top 10 tenants2
  • High quality 1.2 million square foot, $860.2 million3 portfolio composed of eight office and retail condominium assets primarily located in Manhattan
  • 68% of the top 10 tenants portfolio-wide rated as investment grade or implied investment grade4
  • Portfolio occupancy of 88.6% as of September 30, 2020
  • Executed occupancy of 90% and $1 million of additional annual cash rent based on new leases that as of November 1, 2020 that have been signed where the tenant has yet to take possession or commenced paying rent
  • Early 10-year5 lease extension with City National Bank, the largest tenant at 1140 Avenue of the Americas, adding $44 million of gross rent from an investment-grade tenant
  • Executed one lease extension that provided approximately seven months of rent relief in the form of a deferral and rent credit in exchange for a five-year lease extension, providing a net increase of $16.0 million of cash rent
  • Increased weighted-average lease term6 to 7.5 years from 6.6 years at the end of the second quarter 2020
  • Strong balance sheet with net leverage of 36.2%, no debt maturities in the next three years and a weighted average debt maturity of 6.4 years
  • Listed shares of Class A common stock on the New York Stock Exchange on August 18, 2020

“New York City REIT completed a successful third quarter, highlighted by listing our Class A shares on the NYSE, collecting over 85% of the cash rent due in the quarter, and significantly increasing our weighted-average remaining lease term to over 7.5 years, despite the ongoing challenges of the COVID-19 pandemic,” Michael Weil, Chief Executive Officer, commented. “We signed an early, 10-year lease extension with City National Bank, our largest tenant at 1140 Avenue of the Americas worth $44 million of additional cash rent to our future revenue and negotiated a short-term rent deferral in exchange for a five-year lease extension worth $16.0 million. We have built a stable, high-quality pure-play New York City portfolio with occupancy of over 88%, and we remain highly confident in the long-term trends of New York City real estate, our business model, and the opportunities to grow our portfolio while building shareholder value.”

Financial Results

 

 

Three Months Ended September 30,

(In thousands, except per share data)

 

2020

 

2019

Revenue from tenants

 

$

16,997

 

 

$

18,643

 

 

 

 

 

 

Net loss attributable to common stockholders

 

$

(12,288)

 

 

$

(4,809)

 

Net loss per common share (a)

 

$

(0.96)

 

 

$

(0.38)

 

 

 

 

 

 

FFO attributable to common stockholders

 

(3,649)

 

 

2,995

 

FFO per common share (a)

 

$

(0.29)

 

 

$

0.23

 

 

 

 

 

 

Core FFO attributable to common stockholders

 

$

514

 

 

$

3,019

 

Core FFO per common share (a)

 

$

0.04

 

 

$

0.24

 

(a) All per share data based on 12,772,176 and 12,749,456 diluted weighted-average shares outstanding for the three months ended September 30, 2020 and 2019, respectively. 2019 values are retroactively adjusted for the effects of the reverse stock split in August 2020.

Real Estate Portfolio

The Company’s portfolio consisted of eight properties comprised 1.2 million rentable square feet as of September 30, 2020. Portfolio metrics include:

  • 88.6% leased, compared to 92.4% at the end of third quarter 2019, with 7.5 years remaining weighted-average lease term
  • 68% of annualized straight-line rent7 from top 10 tenants derived from investment grade or implied investment grade tenants
  • 76% office (based on an annualized straight-line rent)

Capital Structure and Liquidity Resources

As of September 30, 2020, the Company had $39.1 million of cash and cash equivalents. The Company’s net debt8 to gross asset value9 was 36.2%, with net debt of $365.9 million.

All of the Company’s debt was fixed-rate as of September 30, 2020. The Company’s total combined debt had a weighted-average interest rate of 4.4%10, resulting in an interest coverage ratio of 1.2 times11.

Rent Collection Update

Third Quarter of 2020

For the third quarter of 2020, NYC collected 85% of the cash rents that were due across the portfolio, including 85% of the cash rent payable from the top 10 tenants in the portfolio (based on annualized straight-line rent) and 91% of the cash rent payable from office tenants and 61% of the cash rent payable from retail tenants.

Of the third quarter 2020 cash rent remaining, lease amendments providing for either a rent deferral or a rent credit have been approved for 8% of the unpaid cash rent, while another 6% of rents are currently in negotiation for similar lease amendments. The remaining 1% generally consists of tenants who have made partial payment and/or tenants without active communication on a potential approved agreement.

Footnotes/Definitions

1 This information may not be indicative of any future period. The impact of the COVID-19 pandemic on the Company’s rental revenue for the fourth quarter of 2020 and thereafter cannot be determined at present. The ultimate impact on our future results of operations and liquidity will depend on the overall length and severity of the COVID-19 pandemic, which management is unable to predict. With respect to ongoing negotiations of rent deferrals or credits, there can be no assurance that these negotiations will be successful and will lead to formal agreements on favorable terms, or at all. With respect to the other remaining unpaid amounts, there can be no assurance the Company will be successful in its efforts to collect or defer these amounts on a timely basis, or at all.

2 Top 10 tenants based on annualized straight-line rent as of September 30, 2020.

3 Total real estate investments at cost.

4 As used herein, investment grade includes both actual investment grade ratings of the tenant or guarantor, if available, or implied investment grade. Implied investment grade may include actual ratings of tenant parent, guarantor parent (regardless of whether or not the parent has guaranteed the tenant’s obligation under the lease) or by using a proprietary Moody’s analytical tool, which generates an implied rating by measuring a company’s probability of default. Ratings information is as of September 30, 2020. Top 10 tenants are 56% actual investment grade rated and 12% implied investment grade rated.

5 Assumes tenant does not exercise option to terminate extension term after five years (in 2028) upon payment of termination fee.

6 The weighted-average remaining lease term (years) is based on annualized straight-line rent as of September 30, 2020.

7 Annualized straight-line rent is calculated using the most recent available lease terms as of September 30, 2020.

8 Total debt of $405.0 million less cash and cash equivalents of $39.1 million as of September 30, 2020. Excludes the effect of deferred financing costs, net, mortgage premiums, net and includes the effect of cash and cash equivalents.

9 Defined as the carrying value of total assets of $878.0 million plus accumulated depreciation and amortization of $132.4 million as of September 30, 2020.

10 Weighted based on the outstanding principal balance of the debt.

11The interest coverage ratio is calculated by dividing adjusted EBITDA by cash paid for interest (interest expense less amortization of deferred financing costs, net, and change in accrued interest and amortization of mortgage premiums on borrowings) for the quarter ended September 30, 2020.

Webcast and Conference Call

NYC will host a webcast and call on November 12, 2020 at 11:00 a.m. ET to discuss its financial and operating results. This webcast will be broadcast live over the Internet and can be accessed by all interested parties through the NYC website, www.newyorkcityreit.com, in the “Investor Relations” section.

Dial-in instructions for the conference call and the replay are outlined below.

To listen to the live call, please go to NYC’s “Investor Relations” section of the website at least 15 minutes prior to the start of the call to register and download any necessary audio software. For those who are not able to listen to the live broadcast, a replay will be available shortly after the call on the NYC website at www.newyorkcityreit.com.

Live Call

Dial-In (Toll Free): 1-888-317-6003

International Dial-In: 1-412-317-6061

Canada Dial-In (Toll Free): 1-866-284-3684

Participant Elite Entry Number: 3532909

Conference Replay*

Domestic Dial-In (Toll Free): 1-877-344-7529

International Dial-In: 1-412-317-0088

Canada Dial-In (Toll Free): 1-855-669-9658

Conference Number: 10148253

*Available one hour after the end of the conference call through February 12, 2021

About New York City REIT, Inc.

New York City REIT, Inc. (NYSE: NYC) is a publicly traded real estate investment trust listed on the NYSE that owns a portfolio of high-quality commercial real estate located within the five boroughs of New York City. Additional information about NYC can be found on its website at www.newyorkcityreit.com.

Supplemental Schedules

The Company will file supplemental information packages with the Securities and Exchange Commission (the “SEC”) to provide additional disclosure and financial information. Once posted, the supplemental package can be found under the “Presentations” tab in the Investor Relations section of NYC’s website at www.newyorkcityreit.com and on the SEC website at www.sec.gov.

Important Notice

The statements in this press release that are not historical facts may be forward-looking statements. These forward-looking statements involve substantial risks and uncertainties that could cause the outcome to be materially different. In addition, words such as “may,” “will,” “seeks,” “anticipates,” “believes,” “estimates,” “expects,” “plans,” “intends,” “would,” or similar expressions indicate a forward-looking statement, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those contemplated by such forward-looking statements, including those set forth in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of NYC’s most recent Annual Report on Form 10-K and NYC’s most recent Form 10-Q, as such Risk Factors may be updated from time to time in subsequent reports. Further, forward-looking statements speak only as of the date they are made, and NYC undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time, except as required by law.

New York City REIT, Inc.

Consolidated Balance Sheets

(In thousands. except share and per share data)

 

 

September 30,

2020

 

December 31,

2019

ASSETS

 

(Unaudited)

 

 

Real estate investments, at cost:

 

 

 

 

Land

 

$

193,658

 

 

$

193,658

 

Buildings and improvements

 

568,134

 

 

565,829

 

Acquired intangible assets

 

98,412

 

 

103,121

 

Total real estate investments, at cost

 

860,204

 

 

862,608

 

Less accumulated depreciation and amortization

 

(132,418)

 

 

(114,322)

 

Total real estate investments, net

 

727,786

 

 

748,286

 

Cash and cash equivalents

 

39,088

 

 

51,199

 

Restricted cash

 

9,700

 

 

7,098

 

Operating lease right-of-use asset

 

55,427

 

 

55,579

 

Prepaid expenses and other assets (includes amounts due from related parties of $407 and $0 at September 30, 2020 and December 31, 2019, respectively)

 

11,080

 

 

8,602

 

Straight-line rent receivable

 

25,231

 

 

21,649

 

Deferred leasing costs, net

 

9,643

 

 

8,943

 

Total assets

 

$

877,955

 

 

$

901,356

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

Mortgage notes payable, net

 

$

396,188

 

 

$

395,031

 

Accounts payable, accrued expenses and other liabilities (including amounts due to related parties of $167 and $222 at September 30, 2020 and December 31, 2019, respectively)

 

6,831

 

 

7,033

 

Operating lease liability

 

54,832

 

 

54,866

 

Below-market lease liabilities, net

 

14,517

 

 

18,300

 

Derivative liability, at fair value

 

3,722

 

 

1,327

 

Deferred revenue

 

5,490

 

 

4,250

 

Total liabilities

 

481,580

 

 

480,807

 

 

 

 

 

 

Preferred stock, $0.01 par value, 50,000,000 shares authorized, none issued and outstanding at September 30, 2020 and December 31, 2019

 

 

 

 

Common stock, $0.01 par value, 300,000,000 shares authorized,12,802,690 and 12,755,099 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively

 

129

 

 

128

 

Additional paid-in capital

 

686,690

 

 

686,026

 

Accumulated other comprehensive loss

 

(3,722)

 

 

(1,327)

 

Distributions in excess of accumulated earnings

 

(288,640)

 

 

(264,278)

 

Total stockholders’ equity

 

394,457

 

 

420,549

 

Non-controlling interests

 

1,918

 

 

 

Total equity

 

396,375

 

 

420,549

 

Total liabilities and equity

 

$

877,955

 

 

$

901,356

 

New York City REIT, Inc.

Consolidated Statements of Operations (Unaudited)

(In thousands, except share and per share data)

 

 

Three Months Ended

September 30,

 

 

2020

 

2019

Revenue from tenants

 

$

16,997

 

 

$

18,643

 

 

 

 

 

 

Operating expenses:

 

 

 

 

Asset and property management fees to related parties

 

1,879

 

 

1,962

 

Property operating

 

8,300

 

 

8,026

 

Listing expenses

 

1,299

 

 

 

Vesting and conversion of Class B Units

 

1,153

 

 

 

Equity-based compensation

 

1,711

 

 

24

 

General and administrative

 

1,234

 

 

1,176

 

Depreciation and amortization

 

8,639

 

 

7,804

 

Total operating expenses

 

24,215

 

 

18,992

 

Operating loss

 

(7,218)

 

 

(349)

 

Other income (expense):

 

 

 

 

Interest expense

 

(5,089)

 

 

(4,681)

 

Other income

 

19

 

 

221

 

Total other expense

 

(5,070)

 

 

(4,460)

 

Net loss attributable to common stockholders

 

$

(12,288)

 

 

$

(4,809)

 

 

 

 

 

 

Weighted-average shares outstanding — Basic and Diluted

 

12,772,176

 

 

12,749,456

 

Net loss per share attributable to common stockholders — Basic and Diluted

 

$

(0.96)

 

 

$

(0.38)

 

New York City REIT, Inc.

Quarterly Reconciliation of Non-GAAP Measures (Unaudited)

(In thousands)

 

 

Three Months Ended September 30,

 

 

2020

 

2019

Adjusted EBITDA

 

 

 

 

Net loss

 

$

(12,288)

 

 

$

(4,809)

 

Depreciation and amortization

 

8,639

 

 

7,804

 

Interest expense

 

5,089

 

 

4,681

 

Listing expenses

 

1,299

 

 

 

Vesting and conversion of Class B Units

 

1,153

 

 

 

Equity-based compensation

 

1,711

 

 

24

 

Other income

 

(19)

 

 

(221)

 

Adjusted EBITDA

 

5,584

 

 

7,479

 

Asset and property management fees to related parties

 

1,879

 

 

1,962

 

General and administrative

 

1,234

 

 

1,176

 

NOI

 

8,697

 

 

10,617

 

Accretion of below- and amortization of above-market lease liabilities and assets, net

 

(555)

 

 

(566)

 

Straight-line rent (revenue as a lessor)

 

(2,107)

 

 

(1,267)

 

Straight-line ground rent (expense as lessee)

 

28

 

 

28

 

Cash NOI

 

$

6,063

 

 

$

8,812

 

 

 

 

 

 

Cash Paid for Interest:

 

 

 

 

Interest expense

 

$

5,089

 

 

$

4,681

 

Amortization of deferred financing costs

 

(386)

 

 

(380)

 

Total cash paid for interest

 

$

4,703

 

 

$

4,301

 

New York City REIT, Inc.

Quarterly Reconciliation of Non-GAAP Measures (Unaudited)

(In thousands)

 

 

Three Months Ended September 30,

 

 

2020

 

2019

Net loss attributable to common stockholders

 

$

(12,288)

 

 

$

(4,809)

 

Depreciation and amortization

 

8,639

 

 

7,804

 

FFO attributable to common stockholders

 

(3,649)

 

 

2,995

 

Listing expenses

 

1,299

 

 

 

Vesting and conversion of Class B Units

 

1,153

 

 

 

Equity-based compensation

 

1,711

 

 

24

 

Core FFO attributable to common stockholders

 

$

514

 

 

$

3,019

 

Non-GAAP Financial Measures

This release discusses the non-GAAP financial measures we use to evaluate our performance, including Funds from Operations (“FFO”), Core Funds from Operations (“Core FFO”), Adjusted Earnings before Interest, Taxes, Depreciation and Amortization (“Adjusted EBITDA”), Net Operating Income (“NOI”) and Cash Net Operating Income (“Cash NOI”). While NOI is a property-level measure, Core FFO is based on our total performance and therefore reflects the impact of other items not specifically associated with NOI such as, interest expense, general and administrative expenses and operating fees to related parties. A description of these non-GAAP measures and reconciliations to the most directly comparable GAAP measure, which is net income, is provided below. Adjustments for unconsolidated partnerships and joint ventures are calculated to exclude the proportionate share of the non-controlling interest to arrive at FFO, Core FFO and NOI attributable to stockholders.

Caution on Use of Non-GAAP Measures

FFO, Core FFO, Adjusted EBITDA, NOI and Cash NOI should not be construed to be more relevant or accurate than the current GAAP methodology in calculating net income or in its applicability in evaluating our operating performance. The method utilized to evaluate the value and performance of real estate under GAAP should be construed as a more relevant measure of operational performance and considered more prominently than the non-GAAP measures.

Other REITs may not define FFO in accordance with the current National Association of Real Estate Investment Trusts (“NAREIT”), an industry trade group, definition (as we do), or may interpret the current NAREIT definition differently than we do, or may calculate Core FFO differently than we do. Consequently, our presentation of FFO and Core FFO may not be comparable to other similarly titled measures presented by other REITs.

We consider FFO and Core FFO useful indicators of our performance. Because FFO and Core FFO calculations exclude such factors as depreciation and amortization of real estate assets and gains or losses from sales of operating real estate assets (which can vary among owners of identical assets in similar conditions based on historical cost accounting and useful-life estimates), FFO and Core FFO presentations facilitate comparisons of operating performance between periods and between other REITs in our peer group.

As a result, we believe that the use of FFO and Core FFO, together with the required GAAP presentations, provide a more complete understanding of our performance, including relative to our peers and a more informed and appropriate basis on which to make decisions involving operating, financing, and investing activities. However, FFO and Core FFO are not indicative of cash available to fund ongoing cash needs, including the ability to pay cash dividends. Investors are cautioned that FFO and Core FFO should only be used to assess the sustainability of our operating performance excluding these activities, as they exclude certain costs that have a negative effect on our operating performance during the periods in which these costs are incurred.

Funds from Operations and Adjusted Funds from Operations

Funds from Operations

Due to certain unique operating characteristics of real estate companies, as discussed below, the NAREIT, an industry trade group, has promulgated a performance measure known as FFO, which we believe to be an appropriate supplemental measure to reflect the operating performance of a REIT. FFO is not equivalent to net income or loss as determined under GAAP.

We calculate FFO, a non-GAAP measure, consistent with the standards established over time by the Board of Governors of NAREIT, as restated in a White Paper and approved by the Board of Governors of NAREIT effective in December 2018 (the “White Paper”). The White Paper defines FFO as net income or loss computed in accordance with GAAP, excluding depreciation and amortization related to real estate, gains and losses from sales of certain real estate assets, gain and losses from change in control and impairment write-downs of certain real estate assets and investments in entities when the impairment is directly attributable to decreases in the value of depreciable real estate held by the entity. Adjustments for consolidated partially-owned entities (including our Operating Partnership) and equity in earnings of unconsolidated affiliates are made to arrive at our proportionate share of FFO attributable to our stockholders. Our FFO calculation complies with NAREIT’s definition.

The historical accounting convention used for real estate assets requires straight-line depreciation of buildings and improvements, and straight-line amortization of intangibles. We believe that, because real estate values historically rise and fall with market conditions, including inflation, interest rates, unemployment and consumer spending, presentations of operating results for a REIT using historical accounting for depreciation and certain other items may be less informative. Historical accounting for real estate involves the use of GAAP. Any other method of accounting for real estate such as the fair value method cannot be construed to be any more accurate or relevant than the comparable methodologies of real estate valuation found in GAAP. Nevertheless, we believe that the use of FFO, which excludes the impact of real estate related depreciation and amortization, among other things, provides a more complete understanding of our performance to investors and to management, and when compared year over year, reflects the impact on our operations from trends in occupancy rates, rental rates, operating costs, general and administrative expenses, and interest costs, which may not be immediately apparent from net income.

Core Funds from Operations

In calculating Core FFO, we start with FFO, then we exclude the impact of discrete non-operating transactions and other events which we do not consider representative of the comparable operating results of our real estate operating portfolio, which is our core business platform. Specific examples of discrete non-operating items include acquisition and transaction related costs for dead deals, debt extinguishment costs, listing related costs and expenses (including the vesting and conversion of Class B units and cash expenses and fees which are non-recurring in nature incurred in connection with the listing of Class A common stock on the NYSE and related transactions), and non-cash equity-based compensation. We add back non-cash write-offs of deferred financing costs and prepayment penalties incurred with the early extinguishment of debt which are included in net income but are considered financing cash flows when paid in the statement of cash flows. We consider these write-offs and prepayment penalties to be capital transactions and not indicative of operations. By excluding expensed acquisition and transaction dead deal costs as well as non-operating costs, we believe Core FFO provides useful supplemental information that is comparable for each type of real estate investment and is consistent with management’s analysis of the investing and operating performance of our properties. In future periods, we may also exclude other items from Core FFO that we believe may help investors compare our results.

Adjusted Earnings before Interest, Taxes, Depreciation and Amortization, Net Operating Income and Cash Net Operating Income.

We believe that Adjusted EBITDA, which is defined as earnings before interest, taxes, depreciation and amortization adjusted for acquisition and transaction-related expenses, fees related to the listing related costs and expenses, other non-cash items such as the vesting and conversion of the Class B Units, equity-based compensation expense and including our pro-rata share from unconsolidated joint ventures, is an appropriate measure of our ability to incur and service debt. Adjusted EBITDA should not be considered as an alternative to cash flows from operating activities, as a measure of our liquidity or as an alternative to net income as an indicator of our operating activities. Other REITs may calculate Adjusted EBITDA differently and our calculation should not be compared to that of other REITs.

NOI is a non-GAAP financial measure used by us to evaluate the operating performance of our real estate. NOI is equal to total revenues, excluding contingent purchase price consideration, less property operating and maintenance expense. NOI excludes all other items of expense and income included in the financial statements in calculating net income (loss). We believe NOI provides useful and relevant information because it reflects only those income and expense items that are incurred at the property level and presents such items on an unleveraged basis. We use NOI to assess and compare property level performance and to make decisions concerning the operations of the properties. Further, we believe NOI is useful to investors as a performance measure because, when compared across periods, NOI reflects the impact on operations from trends in occupancy rates, rental rates, operating expenses and acquisition activity on an unleveraged basis, providing perspective not immediately apparent from net income (loss). NOI excludes certain items included in calculating net income (loss) in order to provide results that are more closely related to a property’s results of operations. For example, interest expense is not necessarily linked to the operating performance of a real estate asset. In addition, depreciation and amortization, because of historical cost accounting and useful life estimates, may distort operating performance at the property level. NOI presented by us may not be comparable to NOI reported by other REITs that define NOI differently. We believe that in order to facilitate a clear understanding of our operating results, NOI should be examined in conjunction with net income (loss) as presented in our consolidated financial statements. NOI should not be considered as an alternative to net income (loss) as an indication of our performance or to cash flows as a measure of our liquidity or our ability to pay dividends.

Cash NOI, is a non-GAAP financial measure that is intended to reflect the performance of our properties. We define Cash NOI as NOI excluding amortization of above/below market lease intangibles and straight-line adjustments that are included in GAAP lease revenues. We believe that Cash NOI is a helpful measure that both investors and management can use to evaluate the current financial performance of our properties and it allows for comparison of our operating performance between periods and to other REITs. Cash NOI should not be considered as an alternative to net income, as an indication of our financial performance, or to cash flows as a measure of liquidity or our ability to fund all needs. The method by which we calculate and present Cash NOI may not be directly comparable to the way other REITs present Cash NOI.

Investors and Media:

Email: [email protected]

Phone: (866) 902-0063

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Professional Services Commercial Building & Real Estate Finance Construction & Property REIT Banking

MEDIA:

Logo
Logo

Stratasys Reports Third Quarter 2020 Financial Results

Stratasys Reports Third Quarter 2020 Financial Results

  • Revenue of $127.9 million
  • GAAP net loss of $405.1 million, or ($7.35) per diluted share, and non-GAAP net loss of $3.0 million, or ($0.05) per diluted share; Included in the GAAP net loss was a $386.2 million ($7.01 per share) non-cash goodwill impairment charge.
  • Generated $2.6 million in cash from operations – $308.2 million net cash position with no debt

MINNEAPOLIS & REHOVOT, Israel–(BUSINESS WIRE)–Stratasys Ltd. (NASDAQ: SSYS) announced financial results for the third quarter of 2020.

Q3 2020 Financial Results Summary:

  • Revenue for the third quarter of 2020 was $127.9 million, compared to $157.5 million for the same period last year. The 18.8% reduction was primarily driven by the adverse impact of COVID-19 on the company’s customers throughout the industries into which the company sells its products and services.
  • GAAP gross margin was 38.9% for the quarter, compared to 49.2% for the same period last year. Non-GAAP gross margin was 46.8% for the quarter, compared to 52.4% for the same period last year. GAAP and non-GAAP gross margin improved sequentially from Q2 by 170bp and 140bp, respectively. The company believes that gross margins will continue to recover as and when our customers return to their pre-COVID utilization levels.
  • GAAP operating loss for the quarter was $404.3 million, compared to GAAP operating loss of $6.0 million for the same period last year, mainly due to the non-cash goodwill impairment charge of $386.2 million. Non-GAAP operating loss for the quarter was $1.0 million, compared to non-GAAP operating income of $8.1 million for the same period last year.
  • GAAP net loss for the quarter was $405.1 million, or ($7.35) per diluted share, compared to GAAP net loss of $6.9 million, or ($0.13) per diluted share, for the same period last year, mainly due to the non-cash goodwill impairment charge of $386.2 million. Non-GAAP net loss for the quarter was $3.0 million, or ($0.05) per diluted share, compared to non-GAAP net income of $6.3 million, or $0.12 per diluted share, for the same period last year.
  • Non-GAAP EBITDA was $5.2 million for the quarter, compared to $14.5 million for the same period last year. Non-GAAP EBITDA improved sequentially from Q2 by $6.8 million.
  • The Company recorded a non-cash goodwill impairment charge of $386.2 million, or $7.01 per share, related to the Company’s FDM and PolyJet technologies, primarily as a result of the COVID-19 impact on the Company’s business.
  • The Company generated $2.6 million of cash from operations and ended the period with $308.2 million in cash, cash equivalents and short-term deposits. The Company has no debt.

“We were pleased to see sequential improvements in both our top and bottom lines for this quarter, reflecting the beginning of a potential recovery from the pandemic,” said Yoav Zeif, CEO of Stratasys. “We are laser-focused on leading the polymer 3D printing market by delivering the most innovative, next-gen technologies to address the fastest-growing and most transformative manufacturing applications, while leveraging the strongest go-to-market infrastructure in our industry. We believe that our innovations of today will drive competitive production advantages for the factories of tomorrow, resulting in growth and value creation for our customers and shareholders.”

Stratasys Ltd. Q3 2020 Conference Call Details

The Company plans to hold the conference call to discuss its third quarter 2020 financial results on Thursday, November 12, 2020 at 8:30 a.m. (ET).

The investor conference call will be available via live webcast on the Stratasys Website at investors.stratasys.com, or directly at the following web address: https://78449.themediaframe.com/dataconf/productusers/ssys/mediaframe/41658/indexl.html

To participate by telephone, the U.S. toll-free number is 877-407-0619 and the international dial-in is +1-412-902-1012. Investors are advised to dial into the call at least ten minutes prior to the call to register. The webcast will be available for 6 months at investors.stratasys.com, or by accessing the above-provided web address.

Stratasys (Nasdaq: SSYS) is a global leader in additive manufacturing or 3D printing technology and is the manufacturer of FDM®, PolyJet™, and stereolithography 3D printers. The company’s technologies are used to create prototypes, manufacturing tools, and production parts for industries, including aerospace, automotive, healthcare, consumer products and education. For more than 30 years, Stratasys products have helped manufacturers reduce product-development time, cost, and time-to-market, as well as reduce or eliminate tooling costs and improve product quality. The Stratasys 3D printing ecosystem of solutions and expertise includes 3D printers, materials, software, expert services, and on-demand parts production.

To learn more about Stratasys, visit www.stratasys.com, the Stratasys blog, Twitter, LinkedIn, or Facebook. Stratasys reserves the right to utilize any of the foregoing social media platforms, including the company’s websites, to share material, non-public information pursuant to the SEC’s Regulation FD. To the extent necessary and mandated by applicable law, Stratasys will also include such information in its public disclosure filings.

Stratasys is a registered trademark and the Stratasys signet is a trademark of Stratasys Ltd. and/or its subsidiaries or affiliates. All other trademarks are the property of their respective owners.

Cautionary Statement Regarding Forward-Looking Statements

The statements in this press release regarding Stratasys’ strategy, and the statements regarding its projected future financial performance, are forward-looking statements reflecting management’s current expectations and beliefs. These forward-looking statements are based on current information that is, by its nature, subject to rapid and even abrupt change. Due to risks and uncertainties associated with Stratasys’ business, actual results could differ materially from those projected or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: the degree of our success at introducing new or improved products and solutions that gain market share; the degree of growth of the 3D printing market generally; the duration of the global COVID-19 pandemic, which, if extending for a further significant period of time, may continue to impact, in a material adverse manner, our operations, financial position and cash flows, and those of our customers and suppliers; the impact of potential shifts in the prices or margins of the products that we sell or services that we provide, including due to a shift towards lower-margin products or services; the impact of competition and new technologies; potential further charges against earnings that we could be required to take due to impairment of additional goodwill or other intangible assets; the extent of our success at successfully consummating acquisitions or investments in new businesses, technologies, products or services; potential changes in our management and board of directors; global market, political and economic conditions, and in the countries in which we operate in particular (including risks related to the impact of coronavirus on our operations, supply chain, liquidity, cash flow and customer orders); costs and potential liability relating to litigation and regulatory proceedings; risks related to infringement of our intellectual property rights by others or infringement of others’ intellectual property rights by us; the extent of our success at maintaining our liquidity and financing our operations and capital needs; the impact of tax regulations on our results of operations and financial condition; and those additional factors referred to in Item 3.D “Key Information – Risk Factors”, Item 4, “Information on the Company”, Item 5, “Operating and Financial Review and Prospects,” and all other parts of our Annual Report on Form 20-F for the year ended December 31, 2019 (the “2019 Annual Report”), which we filed with the Securities and Exchange Commission (the “SEC”) on February 26, 2020. Readers are urged to carefully review and consider the various disclosures made throughout our 2019 Annual Report and the Report of Foreign Private Issuer on Form 6-K that attaches Stratasys’ unaudited, condensed consolidated financial statements and its review of its results of operations and financial condition, for the quarterly period ended September 30, 2020, which we are furnishing to the SEC on or about the date hereof, and our other reports filed with or furnished to the SEC, which are designed to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects. Any guidance provided, and other forward-looking statements made, in this press release are made as of the date hereof, and Stratasys undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Use of non-GAAP financial measures

The non-GAAP data included herein, which excludes certain items as described below, are non-GAAP financial measures. Our management believes that these non-GAAP financial measures are useful information for investors and shareholders of our Company in gauging our results of operations on an ongoing basis after (i) excluding mergers, acquisitions and divestments related expense or gains and restructuring-related charges or gains, and (ii) excluding non-cash items such as stock-based compensation expenses, acquired intangible assets amortization, including intangible assets amortization related to equity method investments, impairment of goodwill and long-lived assets, and the corresponding tax effect of those items. These non-GAAP adjustments either do not reflect actual cash outlays that impact our liquidity and our financial condition or have a non-recurring impact on the statement of operations, as assessed by management. These non-GAAP financial measures are presented to permit investors to more fully understand how management assesses our performance for internal planning and forecasting purposes. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of our results of operations without including all items indicated above during a period, which may not provide a comparable view of our performance to other companies in our industry. Investors and other readers should consider non-GAAP measures only as supplements to, not as substitutes for or as superior measures to, the measures of financial performance prepared in accordance with GAAP. Reconciliation between results on a GAAP and non-GAAP basis is provided in a table below.

Stratasys Ltd.
Consolidated Balance Sheets
(Unaudited)
(in thousands, except share data)

September 30,

December 31,

2020

2019

 
 
ASSETS
 
Current assets
Cash and cash equivalents

$

252,906

 

$

293,484

 

Short-term deposits

$

55,300

 

$

28,300

 

Accounts receivable, net

 

103,693

 

 

132,558

 

Inventories

 

152,685

 

 

168,504

 

Prepaid expenses

 

7,568

 

 

6,567

 

Other current assets

 

19,209

 

 

29,659

 

 
Total current assets

 

591,361

 

 

659,072

 

 
Non-current assets
Property, plant and equipment, net

 

198,521

 

 

189,706

 

Goodwill

 

 

 

385,658

 

Other intangible assets, net

 

65,083

 

 

87,328

 

Operating lease right-of-use assets

 

18,905

 

 

20,936

 

Other non-current assets

 

35,238

 

 

38,819

 

 
Total non-current assets

 

317,747

 

 

722,447

 

 
Total assets

$

909,108

 

$

1,381,519

 

 
LIABILITIES AND EQUITY
 
Current liabilities
Accounts payable

$

23,478

 

$

35,818

 

Accrued expenses and other current liabilities

 

26,462

 

 

28,528

 

Accrued compensation and related benefits

 

28,536

 

 

34,013

 

Deferred revenues

 

47,288

 

 

52,268

 

Operating lease liabilities – short term

 

8,675

 

 

9,292

 

 
Total current liabilities

 

134,439

 

 

159,919

 

 
Non-current liabilities
Deferred revenues – long-term

 

13,436

 

 

16,039

 

Operating lease liabilities – long term

 

10,600

 

 

12,445

 

Other non-current liabilities

 

33,291

 

 

35,343

 

 
Total non-current liabilities

 

57,327

 

 

63,827

 

 
Total liabilities

 

191,766

 

 

223,746

 

 
Redeemable non-controlling interests

 

568

 

 

622

 

 
Equity
Ordinary shares, NIS 0.01 nominal value, authorized 180,000 thousands shares; 55,112 thousands shares and 54,441 thousands shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively

 

150

 

 

148

 

Additional paid-in capital

 

2,722,839

 

 

2,706,894

 

Accumulated other comprehensive loss

 

(9,289

)

 

(7,716

)

Accumulated deficit

 

(1,996,926

)

 

(1,542,175

)

Total equity

 

716,774

 

 

1,157,151

 

 
Total liabilities and equity

$

909,108

 

$

1,381,519

 

 
Stratasys Ltd.
Consolidated Statements of Operations
(in thousands, except per share data)
 
Three Months Ended September 30, Nine Months Ended September 30,

2020

2019

2020

2019

(unaudited) (unaudited) (unaudited) (unaudited)
Net sales
Products

$

83,548

 

$

106,346

 

$

240,597

 

$

321,778

 

Services

 

44,344

 

 

51,114

 

 

137,825

 

 

154,145

 

 

127,892

 

 

157,460

 

 

378,422

 

 

475,923

 

 
Cost of sales
Products

 

47,339

 

 

44,341

 

 

126,556

 

 

135,605

 

Services

 

30,784

 

 

35,710

 

 

98,491

 

 

105,285

 

 

78,123

 

 

80,051

 

 

225,047

 

 

240,890

 

 
Gross profit

 

49,769

 

 

77,409

 

 

153,375

 

 

235,033

 

 
Operating expenses
Research and development, net

 

19,562

 

 

23,620

 

 

65,059

 

 

70,234

 

Selling, general and administrative

 

48,343

 

 

59,741

 

 

155,630

 

 

173,217

 

Goodwill impairment

 

386,154

 

 

 

 

386,154

 

 

 

 

454,059

 

 

83,361

 

 

606,843

 

 

243,451

 

 
Operating loss

 

(404,290

)

 

(5,952

)

 

(453,468

)

 

(8,418

)

 
Financial income (expense), net

 

(167

)

 

289

 

 

(847

)

 

2,796

 

 
Loss before income taxes

 

(404,457

)

 

(5,663

)

 

(454,315

)

 

(5,622

)

 
Income tax expenses (benefit)

 

(343

)

 

586

 

 

(2,250

)

 

3,084

 

 
Share in profits (losses) of associated companies

 

(952

)

 

(733

)

 

(2,740

)

 

495

 

 
Net Loss

 

(405,066

)

 

(6,982

)

 

(454,805

)

 

(8,211

)

 
Net loss attributable to non-controlling interests

 

(4

)

 

(41

)

 

(54

)

 

(152

)

 
Net loss attributable to Stratasys Ltd.

$

(405,062

)

$

(6,941

)

$

(454,751

)

$

(8,059

)

 
Net loss per ordinary share attributable to Stratasys Ltd.
Basic

$

(7.35

)

$

(0.13

)

$

(8.29

)

$

(0.15

)

Diluted

$

(7.35

)

$

(0.13

)

$

(8.29

)

$

(0.15

)

 
 
Basic

 

55,086

 

 

54,394

 

 

54,851

 

 

54,201

 

Diluted

 

55,086

 

 

54,394

 

 

54,851

 

 

54,201

 

 
     
   

Three Months Ended September 30,

   

2020

 

Non-GAAP

 

2020

 

2019

 

Non-GAAP

 

2019

   

GAAP

 

Adjustments

 

Non-GAAP

 

GAAP

 

Adjustments

 

Non-GAAP

   

U.S. dollars and shares in thousands (except per share amounts)

     
  Gross profit (1)  

$

49,769

 

$

10,036

 

$

59,805

 

$

77,409

 

$

5,087

 

$

82,496

  Operating income (loss) (1,2)  

 

(404,290

)

 

403,268

 

 

(1,022

)

 

(5,952

)

 

14,055

 

 

8,103

  Net income (loss) attributable to Stratasys Ltd. (1,2,3)  

 

(405,062

)

 

402,050

 

 

(3,012

)

 

(6,941

)

 

13,275

 

 

6,334

  Net income (loss) per diluted share attributable to Stratasys Ltd. (4)  

$

(7.35

)

$

7.30

 

$

(0.05

)

$

(0.13

)

$

0.25

 

$

0.12

     
     

(1)

  Acquired intangible assets amortization expense  

 

4,065

 

 

3,916

 

  Non-cash stock-based compensation expense  

 

524

 

 

475

 

  Restructuring and other related costs  

 

191

 

 

696

 

  Impairment charges of intangible assets  

 

5,256

 

 

 

   

 

10,036

 

 

5,087

 

     

(2)

  Acquired intangible assets amortization expense  

 

2,162

 

 

2,016

 

  Non-cash stock-based compensation expense  

 

4,352

 

 

4,960

 

  Goodwill impairment  

 

386,154

 

 

 

  Restructuring and other related costs  

 

34

 

 

1,992

 

  Other expenses  

 

530

 

 

 

   

 

393,232

 

 

8,968

 

   

 

403,268

 

 

14,055

 

     

(3)

  Corresponding tax effect  

 

(1,296

)

 

(780

)

  Equity method related amortization, divestments and impairments  

 

78

 

 

 

   

$

402,050

 

$

13,275

 

(4)

  Weighted average number of ordinary shares outstanding- Diluted  

 

55,086

 

 

55,086

 

 

54,394

 

 

54,940

     
   

Nine Months Ended September 30,

   

2020

 

Non-GAAP

 

2020

 

2019

 

Non-GAAP

 

2019

   

GAAP

 

Adjustments

 

Non-GAAP

 

GAAP

 

Adjustments

 

Non-GAAP

   

U.S. dollars and shares in thousands (except per share amounts)

     
  Gross profit (1)  

$

153,375

 

$

24,062

 

$

177,437

 

$

235,033

 

$

13,780

 

$

248,813

  Operating income (loss) (1,2)  

 

(453,468

)

 

435,987

 

 

(17,481

)

 

(8,418

)

 

32,376

 

 

23,958

  Net income (loss) attributable to Stratasys Ltd. (1,2,3)  

 

(454,751

)

 

433,821

 

 

(20,930

)

 

(8,059

)

 

28,574

 

 

20,515

  Net income (loss) per diluted share attributable to Stratasys Ltd. (4)  

$

(8.29

)

$

7.91

 

$

(0.38

)

$

(0.15

)

$

0.53

 

$

0.38

     
     

(1)

  Acquired intangible assets amortization expense  

 

12,196

 

 

11,714

 

  Non-cash stock-based compensation expense  

 

1,424

 

 

1,370

 

  Restructuring and other related costs  

 

5,187

 

 

696

 

  Impairment charges of intangible assets  

 

5,256

 

 

 

   

 

24,062

 

 

13,780

 

     

(2)

  Acquired intangible assets amortization expense  

 

6,430

 

 

5,688

 

  Non-cash stock-based compensation expense  

 

14,470

 

 

14,387

 

  Goodwill impairment  

 

386,154

 

 

 

  Restructuring and other related costs  

 

3,863

 

 

(1,479

)

  Other expenses  

 

1,007

 

 

 

   

 

411,925

 

 

18,596

 

   

 

435,987

 

 

32,376

 

     

(3)

  Corresponding tax effect  

 

(2,396

)

 

(2,198

)

  Equity method related amortization, divestments and impairments  

 

230

 

 

(1,604

)

   

$

433,821

 

$

28,574

 

     

(4)

  Weighted average number of ordinary shares outstanding- Diluted  

 

54,851

 

 

54,851

 

 

54,201

 

 

54,705

 

Stratasys Investor Relations

Yonah Lloyd

Vice President – Investor Relations

[email protected]

KEYWORDS: United States North America Israel Middle East Minnesota

INDUSTRY KEYWORDS: Automotive Manufacturing Aerospace Technology Manufacturing Other Technology Other Manufacturing Software Packaging Engineering Hardware Chemicals/Plastics

MEDIA:

Vecima Reports Q1 Fiscal 2021 Results

Vecima Reports Q1 Fiscal 2021 Results

  • Revenue – $27.8M, Gross Margin – 47%, Cash Balance – $27.3M
  • Grew Q1 Adjusted EBITDA 24% year-over-year to $2.2M
  • Achieved record Q1 Entra sales of $5.2M, increasing $4.9M year-over-year and $3.1M (147%) sequentially
  • Completed acquisition of Nokia’s cable access portfolio of DAA and EPON/DPoE solutions, creating industry’s most comprehensive next generation access ecosystem and significantly accelerating Vecima’s 10G technology timeline

VICTORIA, British Columbia–(BUSINESS WIRE)–
Vecima Networks Inc. (TSX:VCM) today reported financial results for the three months ended September 30, 2020.

FINANCIAL HIGHLIGHTS

(Canadian dollars in millions except percentages, employees, and per share data)

Q1FY21

Q4FY20

 

Q1FY20

Revenue

$27.8

$26.1

 

$20.1

Gross Margin

47%

49%

 

52%

Net Loss

$(0.8)

$(1.0)

 

$(1.4)

Loss Per Share1

$(0.04)

$(0.05)

 

$(0.06)

Adjusted Loss Per Share1, 2, 3

$(0.04)

$(0.06)

 

$(0.06)

Adjusted EBITDA2

$2.2

$3.8

 

$1.8

Cash and Short-term Investments

$27.3

$34.5

 

$41.3

Employees4

456

377

 

366

1Based on weighted average number of shares outstanding.

2Adjusted Earnings/(Loss) Per Share and Adjusted EBITDA do not have a standardized meaning under IFRS and therefore may not be comparable to similar measures provided by other issuers. See “Adjusted EBITDA and Adjusted Earnings/(Loss) Per Share” below.

3Starting in Q4 fiscal 2019, we have changed our definition and calculation of Adjusted Earnings Per Share. For a reconciliation of Adjusted Earnings Per Share, investors should refer to Vecima’s Management’s Discussion and Analysis for the first quarter of fiscal 2021.

4Includes employees and contractors from recently acquired business

“In a year in which we anticipate significant growth, we set the stage by increasing first quarter revenue by 38% to $27.8 million, our best quarterly result in over four years,” said Sumit Kumar, Vecima’s President and CEO. “Our strong topline results were accompanied by gross profit of $13.0 million and adjusted EBITDA of $2.2 million, which were both up 24% as compared to Q1 fiscal 2020.”

“In the Video and Broadband Solutions segment, sales of $13.5 million increased by a very significant 81% year-over-year. This was led by strong sales growth for our new Entra products as the distributed access architecture market kicked off. I am delighted to report that Entra revenues rose sharply to $5.2 million during the quarter, coming close to matching in just three months what we achieved in all of fiscal 2020. The Entra growth was driven by production deployments of our industry-leading Entra Remote PHY Node to our lead Tier 1 customer, as well as initial deployment-related Remote PHY Node purchases made by multiple additional operators. Sales of the Entra Interactive Video Controller (IVC) product also grew significantly, and our newly acquired DAA portfolio, which includes Remote MAC-PHY and EPON/DPoE technologies, contributed approximately $1 million to first quarter Entra sales. Video and Broadband Solutions sales were further bolstered by a significant year-over-year increase in TerraceQAM commercial video sales during the period.”

“In our Content Delivery and Storage segment, we achieved solid revenue of $13.0 million in what is traditionally the seasonally slowest quarter for this segment,” added Mr. Kumar. “CDS sales were up 15% year-over-year as we consolidated the major new business wins of fiscal 2020. We also added two new customer wins during the quarter, securing an additional two IPTV conversions. Our MediaScaleX solutions are now in use by over 100 cable companies, telcos and broadcasters worldwide, translating into a vast base for the future given that most of these customers are just starting their migration to IPTV and scale subscriber uptake remains ahead of Vecima and our customers.”

BUSINESS HIGHLIGHTS

Video and Broadband Solutions (VBS)

  • The VBS segment delivered exceptional growth as anticipated with first quarter revenue growing 81% year-over-year and 29% quarter-over-quarter as customers began the transition to next generation networks using platforms across Vecima’s portfolio.

Entra Family

  • Deployments of next generation Entra DAA products, tied to the earliest stages of the DAA market, contributed sales of $5.2 million, increasing $4.9 million year-over-year and $3.1 million (147%) sequentially. In the first quarter of fiscal 2021 alone, Vecima achieved 98% of the Entra sales we realized in the full fiscal 2020 period.
  • Production deployments of the industry-leading, multi-core interoperable Entra Remote PHY Node increased at the lead Tier 1 customer and deployment-related purchases were initiated at multiple additional MSOs in the first quarter. Combined with the Entra Remote MAC-PHY Node and 10G EPON solutions, Entra DAA platforms have now been sold to over a dozen operators in five continents.
  • Vecima’s global engagements for the broader Entra portfolio have widened to include 46 MSOs, including operators in the US, Canada, CALA, EMEA, and APAC. This includes over 40 operators that are either in lab trial, field trial, or live deployment phases across the globe.
  • On August 7, 2020, Vecima significantly expanded and accelerated its Entra offering with the acquisition of Nokia’s cable access business. The acquired portfolio includes market-deployed Remote MAC-PHY, access controller and 10G EPON products, and has positioned Vecima as the industry’s leading provider of DAA technologies. Today, Vecima’s Entra offers the broadest full complement of access network solutions in the industry, spanning the varied needs of cable operators globally. In addition to a powerful suite of platforms and technology, the transaction brought Vecima new facilities in the US and China, and a talented team of over 80 employees that have joined the Company.
  • Subsequent to quarter-end, Vecima was awarded the prestigious Chairman’s Advanced Technology Award in the Network Hardware category at the 2020 SCTE-ISBE Cable-Tec Expo. The awards were presented to an elite group of technology partners who are helping the cable industry bring the 10G platform to life by paving the way for cable to deliver residential internet speeds up to 10X faster than today’s network. The SCTE-ISBE chose to honour recipient companies that are laying the foundation for a host of applications that will change the ways we interact with one another and the world around us.
  • On October 14, 2020, Vecima was honored with a BTR Diamond Technology Review Award for the Entra EN 2112 Access Node, one of the most compact and feature-rich nodes available today.

Commercial Video (Terrace) Family

  • TerraceQAM sales grew to $4.2 million, up 120% from $1.9 million in Q1 fiscal 2020 and 25% from $3.3 million in Q4 fiscal 2020. The lead Tier 1 MSO continued to widen its extensive hospitality service platform, while preparing for migration to the next generation Terrace IQ system.
  • Terrace family sales of $3.5 million provided ongoing contribution as Tier 1 customers neared full coverage leading up to the migration to next generation platforms.
  • Subsequent to the quarter-end, Vecima was honored with a BTR Diamond Technology Review Award for the Terrace IQ Commercial Video Gateway. Terrace IQ enables seamless migration to next generation IP video delivery technologies with minimal hardware investments when migrating away from traditional architectures.

Content Delivery and Storage (CDS)

  • CDS segment sales increased to $13.0 million in Q1, a 15% increase from Q1 fiscal 2020.
  • Vecima won two new customers for its MediaScaleX IPTV solutions, securing an additional two IPTV conversions during the quarter.
  • The migration to IPTV technologies, including IP Linear broadcast , “over the top”, Video on Demand, start-over/catch-up TV, & cloud DVR, continued in full force across Vecima’s global customer base, driving increased capacity and network utilization. Record-high IPTV streaming levels were delivered by MediaScaleX networks across nearly all customers.
  • Vecima provided the IP streaming solution for a Tier 2 operator’s 8K Ultra HD resolution delivery, a first-of-its-kind service in North America.
  • Major feature enhancements were rolled out across the customer base in the first quarter including advances in DRM, Dynamic Ad Insertion, resiliency to external network issues, and virtualization.

Telematics

  • The Telematics segment increased engagement with municipal government customers, with two expansions totaling over 300 subscribers.
  • Vecima continued to penetrate the moveable assets market, securing four new customers and approximately 100 additional subscribers in the restoration industry, where vehicles are monitored using GPS beacons and valuable moveable assets are monitored through Bluetooth Low Energy (BLE) tags.

“We believe the momentum achieved in the first quarter is just the start of what’s in store for fiscal 2021,” added Mr. Kumar. “We anticipate continued ramp in Entra DAA sales, particularly in the second half as our lead customers transition to scale deployment and a broader set of MSOs initiate field deployments of DAA to respond to network capacity pressures being seen globally. Our newly acquired Remote MAC-PHY and EPON/DPoE solutions are already performing well and the build-up of overall market activity we see with the combined portfolio is very exciting and fully in line with our expectations after having created the industry’s best access network product lineup. We will continue to leverage the strong opportunities provided by these leading products in the once-in-a-lifetime network upgrade they cover. In our Content Delivery and Storage segment, we continue to anticipate measured sales growth in FY2021 as we consolidate the record-setting customer wins of last year and IPTV usage continues to increase rapidly in households globally.”

“As we move forward, we remain highly confident in our view that fiscal 2021 will be a breakthrough year for Vecima. The move to DAA and IPTV is underway and we are ideally positioned with an unmatched portfolio of industry-leading, next generation solutions and platforms,” said Mr. Kumar.

As previously reported, Vecima’s Board of Directors declared a quarterly dividend of $0.055 per share for the period. The dividend will be payable on December 21, 2020 to shareholders of record as at November 27, 2020.

CONFERENCE CALL

A conference call and live audio webcast will be held today, November 12, 2020 at 1 p.m. ET to discuss the Company’s first quarter results. Vecima’s unaudited condensed interim consolidated financial statements and management’s discussion and analysis for the three months ended September 30, 2020 are available under the Company’s profile at www.SEDAR.com, and at www.vecima.com/financials/.

To participate in the teleconference, dial 1-800-319-4610 or 1-604-638-9020. The webcast will be available in real time at http://services.choruscall.ca/links/vecima20201112.htmland will bearchived on the Vecima website athttps://vecima.com/investor-relations/earnings-call-archive/.

About Vecima Networks

Vecima Networks Inc. is a global leader focused on developing integrated hardware and scalable software solutions for broadband access, content delivery, and telematics. We enable the world’s leading innovators to advance, connect, entertain, and analyze. We build technologies that transform content delivery and storage, enable high‑capacity broadband network access, and streamline data analytics. For more information, please visit our website at www.vecima.com.

Adjusted EBITDA and Adjusted Earnings / (Loss) Per Share

Adjusted EBITDA and Adjusted Earnings / (Loss) Per Share do not have a standardized meaning under IFRS and therefore may not be comparable to similar measures provided by other issuers. Accordingly, investors are cautioned that Adjusted EBITDA or Adjusted Earnings / (Loss) Per Share should not be construed as an alternative to net income, determined in accordance with IFRS, as an indicator of the Company’s financial performance or as a measure of its liquidity and cash flows. For a reconciliation of Adjusted EBITDA or Adjusted Earnings / (Loss) Per Share, investors should refer to Vecima’s Management’s Discussion and Analysis for the first quarter of fiscal 2021.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information is generally identifiable by use of the words “believes”, “may”, “plans”, “will”, “anticipates”, “intends”, “could”, “estimates”, “expects”, “forecasts”, “projects” and similar expressions, and the negative of such expressions. Forward-looking information in this news release includes the following statements: We set the stage for a year where we plan significant growth; our MediaScaleX solutions are now in use by over 100 cable companies, telcos and broadcasters worldwide, translating into a vast base for the future given that most of these customers are just starting their migration to IPTV and scale subscriber uptake remains ahead of Vecima and our customers; the VBS segment delivered exceptional growth as anticipated; the acquired portfolio has positioned Vecima as the industry’s leading provider of DAA technologies; Vecima’s Entra offers the broadest full complement of access network solutions in the industry, spanning the varied needs of cable operators globally; we believe the momentum achieved in the first quarter is just the start of what’s in store for fiscal 2021; we anticipate continued ramp in Entra DAA sales, particularly in the second half as our lead customers transition to scale deployment and a broader set of MSOs initiate field deployments of DAA to respond to network capacity pressures being seen globally; our newly acquired Remote MAC-PHY and EPON/DPoE solutions are already performing well and the build-up of overall market activity we see with the combined portfolio is very exciting and fully in line with our expectations after having created the industry’s best access network product lineup; we will continue to leverage the strong opportunities provided by these leading products in the once-in-a-lifetime network upgrade they cover; in our Content Delivery and Storage segment, we continue to anticipate measured sales growth in FY2021 as we consolidate the record-setting customer wins of last year and IPTV usage continues to increase rapidly in households globally; as we move forward, we remain highly confident in our view that fiscal 2021 will be a breakthrough year for Vecima; the move to DAA and IPTV is underway and we are ideally positioned with an unmatched portfolio of industry-leading, next generation solutions and platforms.

A more complete discussion of the risks and uncertainties facing Vecima is disclosed under the heading “Risk Factors” in the Company’s Annual Information Form dated September 24, 2020, as well as the Company’s continuous disclosure filings with Canadian securities regulatory authorities available at www.sedar.com. All forward-looking information herein is qualified in its entirety by this cautionary statement, and Vecima disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

 

VECIMA NETWORKS INC.

Consolidated Statements of Financial Position

(in thousands of Canadian dollars)

As at

 

 

September 30, 2020

 

 

June 30, 2020

Assets

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

Cash and cash equivalents

 

 

$

10,432

 

$

17,350

Short-term investments

 

 

 

16,910

 

 

17,165

Accounts receivable

 

 

 

23,058

 

 

24,908

Income tax receivable

 

 

 

362

 

 

333

Inventories

 

 

 

21,337

 

 

17,212

Prepaid expenses

 

 

 

1,707

 

 

2,051

Contract assets

 

 

 

704

 

 

646

Total current assets

 

 

 

74,510

 

 

79,665

Non-current assets

 

 

 

 

 

 

 

Property, plant and equipment

 

 

 

14,539

 

 

11,801

Right-of-use assets

 

 

 

3,620

 

 

4,010

Goodwill

 

 

 

15,594

 

 

15,487

Intangible assets

 

 

 

70,189

 

 

69,200

Other long-term assets

 

 

 

1,246

 

 

1,301

Investment tax credits

 

 

 

24,732

 

 

24,374

Deferred tax assets

 

 

 

4,870

 

 

4,460

Total assets

 

 

$

209,300

 

$

210,298

Liabilities and shareholders’ equity

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

Accounts payable and accrued liabilities

 

 

$

17,391

 

$

17,105

Provisions

 

 

 

1,285

 

 

492

Income tax payable

 

 

 

3

 

 

130

Deferred revenue

 

 

 

4,776

 

 

4,960

Other current liabilities

 

 

 

1,245

 

 

Current portion of long-term debt

 

 

 

1,752

 

 

1,698

Total current liabilities

 

 

 

26,452

 

 

24,385

Non-current liabilities

 

 

 

 

 

 

 

Provisions

 

 

 

412

 

 

400

Deferred revenue

 

 

 

698

 

 

602

Deferred tax liability

 

 

 

7

 

 

536

Long-term debt

 

 

 

4,132

 

 

4,613

Total liabilities

 

 

 

31,701

 

 

30,536

Shareholders’ equity

 

 

 

 

 

 

 

Share capital

 

 

 

3,556

 

 

3,161

Reserves

 

 

 

3,975

 

 

3,838

Retained earnings

 

 

 

168,582

 

 

170,665

Accumulated other comprehensive income

 

 

 

1,486

 

 

2,098

Total shareholders’ equity

 

 

 

177,599

 

 

179,762

Total liabilities and shareholders’ equity

 

 

$

209,300

 

$

210,298

 

 

 

 

 

 

 

 

VECIMA NETWORKS INC.

Consolidated Statements of Comprehensive Loss

(in thousands of Canadian dollars, except per share amounts)

 

 

Three months ended September 30,

 

 

 

 

 

 

 

2020

 

 

2019

Sales

 

 

 

 

 

$

27,844

 

$

20,112

Cost of Sales

 

 

 

 

 

 

14,836

 

 

9,638

Gross Profit

 

 

 

 

 

 

13,008

 

 

10,474

Operating expenses

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

 

 

 

 

6,343

 

 

5,068

Sales and marketing

 

 

 

 

 

 

3,209

 

 

3,746

General and administrative

 

 

 

 

 

 

4,791

 

 

3,981

Share-based compensation

 

 

 

 

 

 

239

 

 

17

Other (income) expense

 

 

 

 

 

 

(3)

 

 

(10)

Total operating expenses

 

 

 

 

 

 

14,579

 

 

12,802

Operating loss

 

 

 

 

 

 

(1,571)

 

 

(2,328)

Finance income

 

 

 

 

 

 

161

 

 

208

Foreign exchange (loss) gain

 

 

 

 

 

 

(225)

 

 

298

Loss before income taxes

 

 

 

 

 

 

(1,635)

 

 

(1,822)

Income tax recovery

 

 

 

 

 

 

(797)

 

 

(438)

Net loss

 

 

 

 

 

$

(838)

 

$

(1,384)

Other comprehensive (loss) income

 

 

 

 

 

 

 

 

 

 

Item that may be subsequently reclassed to net income

 

 

 

 

 

 

Exchange differences on translating foreign operations

 

 

 

(612)

 

 

223

Comprehensive loss

 

 

 

 

 

$

(1,450)

 

$

(1,161)

Net loss per share

 

 

 

 

 

 

 

 

 

 

Basic

 

 

 

 

 

$

(0.04)

 

$

(0.06)

Diluted

 

 

 

 

 

$

(0.04)

 

$

(0.06)

Weighted average number of common shares

 

 

 

 

 

 

 

 

 

Shares outstanding – basic

 

 

 

22,482,015

 

22,370,087

Shares outstanding – diluted

 

 

 

 

22,482,015

 

22,370,087

 

VECIMA NETWORKS INC.

Consolidated Statements of Change in Equity

(in thousands of Canadian dollars)

 

 

 

Share

capital

 

 

Reserves

 

 

Retained

earnings

 

 

Accumulated

other

comprehensive

income

 

 

Total

 

Balance as at June 30, 2019

 

$

1,916

 

$

4,104

 

$

173,898

 

$

1,010

 

$

180,928

Net loss

 

 

 

 

 

 

(1,384)

 

 

 

 

(1,384)

Other comprehensive income

 

 

 

 

 

 

 

 

223

 

 

223

Dividends

 

 

 

 

 

 

(1,231)

 

 

 

 

(1,231)

Share-based payment expense

 

 

 

 

17

 

 

 

 

 

 

17

Balance as at September 30, 2019

 

$

1,916

 

$

4,121

 

$

171,283

 

$

1,233

 

$

178,553

Balance as at June 30, 2020

 

$

3,161

 

$

3,838

 

$

170,665

 

$

2,098

 

$

179,762

Net loss

 

 

 

 

 

 

(838)

 

 

 

 

(838)

Other comprehensive loss

 

 

 

 

 

 

 

 

(612)

 

 

(612)

Dividends

 

 

 

 

 

 

(1,245)

 

 

 

 

(1,245)

Shares issued by exercising options

 

 

395

 

 

(102)

 

 

 

 

 

 

293

Share-based payment expense

 

 

 

 

239

 

 

 

 

 

 

239

Balance as at September 30, 2020

 

$

3,556

 

$

3,975

 

$

168,582

 

$

1,486

 

$

177,599

           

VECIMA NETWORKS INC.

Consolidated Statements of Cash Flows

(in thousands of Canadian dollars)

 

Three months ended September 30,

 

 

 

 

 

 

2020

 

 

2019

OPERATING ACTIVITIES

 

 

 

 

 

 

 

 

 

Net loss

 

 

 

 

$

(838)

 

$

(1,384)

Adjustments for non-cash items:

 

 

 

 

 

 

 

 

 

Loss on sale of property, plant and equipment

 

 

 

 

 

2

 

 

14

Depreciation and amortization

 

 

 

 

 

3,542

 

 

3,496

Share-based compensation

 

 

 

 

 

239

 

 

17

Income tax (recovery) expense

 

 

 

 

 

(577)

 

 

526

Deferred income tax recovery

 

 

 

 

 

(220)

 

 

(964)

Interest expense

 

 

 

 

 

59

 

 

80

Interest income

 

 

 

 

 

(88)

 

 

(222)

Net change in working capital

 

 

 

 

 

1,348

 

 

(1,193)

Decrease in other long-term assets

 

 

 

 

 

43

 

 

6

Increase in provisions

 

 

 

 

 

11

 

 

Increase in investment tax credits

 

 

 

 

 

(41)

 

 

(38)

Income tax paid

 

 

 

 

 

(125)

 

 

(22)

Interest received

 

 

 

 

 

88

 

 

222

Interest paid

 

 

 

 

 

(10)

 

 

(80)

Cash provided by operating activities

 

 

 

 

 

3,433

 

 

458

INVESTING ACTIVITIES

 

 

 

 

 

 

 

 

 

Capital expenditures, net

 

 

 

 

 

(449)

 

 

(444)

Purchase of short-term investments

 

 

 

 

 

(84)

 

 

(200)

Proceeds from sale of short-term investments

 

 

 

 

 

339

 

 

1,400

Deferred development costs

 

 

 

 

 

(3,448)

 

 

(2,650)

Business acquisition

 

 

 

 

 

(6,401)

 

 

Cash used in investing activities

 

 

 

 

 

(10,043)

 

 

(1,894)

FINANCING ACTIVITIES

 

 

 

 

 

 

 

 

 

Proceeds from government grants

 

 

 

 

 

 

 

31

Principal payments of lease liabilities

 

 

 

 

 

(375)

 

 

(332)

Repayment of long-term debt

 

 

 

 

 

(63)

 

 

(83)

Issuance of shares through exercised options

 

 

 

 

 

293

 

 

Cash used in financing activities

 

 

 

 

 

(145)

 

 

(384)

Net decrease in cash and cash equivalents

 

 

 

 

 

(6,755)

 

 

(1,820)

Effect of change in exchange rates on cash

 

 

 

 

 

(163)

 

 

(51)

Cash and cash equivalents, beginning of period

 

 

 

 

 

17,350

 

 

19,834

Cash and cash equivalents, end of period

 

 

 

 

$

10,432

 

$

17,963

 

Vecima Networks

Investor Relations – 250-881-1982

[email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Telecommunications Software Audio/Video Hardware TV and Radio Technology VoIP Entertainment

MEDIA:

Logo
Logo

Radware Reports Results of 2020 Annual General Meeting

TEL AVIV, Israel, Nov. 12, 2020 (GLOBE NEWSWIRE) — Radware® (NASDAQ: RDWR), a leading provider of cyber security and application delivery solutions, today announced the results of its Annual General Meeting of Shareholders held November 10, 2020. The Company presented six proposals for the shareholders to vote on at the meeting. All six proposals voted on at the Annual General Meeting were adopted by the requisite shareholder vote.

About Radware


Radware
® (NASDAQ: RDWR), is a global leader of cyber security and application delivery solutions for physical, cloud, and software defined data centers. Its award-winning solutions portfolio secures the digital experience by providing infrastructure, application, and corporate IT protection and availability services to enterprises globally. Radware’s solutions empower enterprise and carrier customers worldwide to adapt to market challenges quickly, maintain business continuity and achieve maximum productivity while keeping costs down. For more information, please visit www.radware.com.

The contents of any website or hyperlinks mentioned in this press release are for informational purposes and the contents thereof are not part of this press release.

Media Contacts:

Deborah Szajngarten
Radware
201-785-3206
[email protected]

Investor Relations:

Anat Earon-Heilborn
+972 723917548
[email protected]

COVID-19 has led to an increased awareness of Financial Wellness

Equifax Survey finds that over 70 per cent of surveyed consumers have checked their credit report within the last year

TORONTO, Nov. 12, 2020 (GLOBE NEWSWIRE) — People are checking their credit reports and scores more frequently and are taking identity theft more seriously as compared to previous years, according to a recent consumer survey conducted by Equifax Canada.

COVID-19 has caused many people to take a closer look at their financial situation, which is resulting in an increased understanding about their relationship with credit. Within the last 12 months, 71 per cent of survey respondents have checked their credit report, including 57 per cent in the last month. Younger adults (under age 55) and Quebecers were significantly more likely to have checked their credit reports on a regular basis. This is a significant shift for consumers when considering 67 per cent of survey respondents ‘rarely or never checked their credit reports’ according to a similar survey conducted by Equifax in 2016.

“The pandemic has clearly impacted everyone so much that more people feel the need to assess their financial situation,” said Rebecca Oakes, Equifax Canada’s AVP of Advanced Analytics. “Checking your credit reports and obtaining credit scores is a good place to start. It’s actually encouraging to see a higher percentage of people checking their credit reports and scores now compared to a few years ago.”

Equifax Canada data indicates that payment deferrals have been utilized with over 3 million consumers taking a payment deferral since the pandemic started. Thus far, 14 per cent of open mortgages have had at least one month of payment deferral (approximately 900,000 deferred mortgages) and two per cent of open credit cards have had at least one month of payment deferral (approximately 1.2 million deferred credit cards). About half of deferred mortgages have had continued deferred payments for the past four months, while credit cards have had a shorter deferral duration of one or two months.

CREDIT SCORES ALSO CHECKED MORE FREQUENTLY

In addition to checking their credit reports, survey respondents indicated they are obtaining their credit scores more frequently. More than half (54 per cent) said they obtain their score at least annually, as compared to 48 per cent a year ago. Younger adults (those aged 18-34) are significantly more likely to check their credit scores monthly versus those over the age of 35 (37 per cent in 2020 vs. 27 per cent in 2019).

“COVID-19 has caused many Canadian households to develop a better understanding of their finances on the fly,” said Keith Emery, Co-CEO of Credit Canada. “Knowing what’s in your credit reports and how credit scores are calculated are important steps towards improved financial wellness. We always caution people to avoid anyone offering to ‘fix’ your credit score. The best road to a healthy credit score is making bill payments on time. It’s as simple as that.”

STEPS TO PREVENTING IDENTITY THEFT

Equifax data collected and analyzed from its consortium of lenders and industry partners also indicates that fraudsters and identity thieves are more active and looking to take advantage of the COVID-19 crisis. Since the pandemic began, the application fraud rate has increased by 43 per cent and the deposit account fraud rate rose by 53 per cent peaking in April and May respectively.

Fortunately, survey results indicate that Canadians continue to take the threat of fraud and identity theft seriously. When comparing survey results to four years ago the numbers are trending in the right direction. More people are taking precautionary steps to help protect against fraud and identity theft.

2020 Steps Taken by Consumers 2016
83% Review credit card statements on receipt for fraudulent activity 79%
65% Check my credit report 28%
59% Avoid using public Wi-Fi 47%
54% Update security passwords 43%

“Identity thieves and fraudsters are quick to take advantage of any crisis,” said Oakes. “COVID-19 has forced many people to work online from home, buy their groceries online, and in a lot of cases stay socially connected to friends and family online. Spending more time online safely requires making sure you are taking steps to help protect yourself. Checking your credit report regularly remains one of the best ways to recognize and help protect against fraud and identity theft.”

To learn more about fraud prevention and how credit works, consumers are encouraged to visit Equifax Canada’s education hub. The site offers insights on how different actions may affect their credit scores and provides resources to help improve their financial wellness.

*An online survey of 1,539 Canadians was completed between September 11-13, 2020, using Leger’s online panel. The margin of error for this study was +/-2.5%, 19 times out of 20.

About Equifax
At Equifax (NYSE: EFX), we believe knowledge drives progress. As a global data, analytics, and technology company, we play an essential role in the global economy by helping financial institutions, companies, employees, and government agencies make critical decisions with greater confidence. Our unique blend of differentiated data, analytics, and cloud technology drives insights to power decisions to move people forward. Headquartered in Atlanta and supported by more than 11,000 employees worldwide, Equifax operates or has investments in 25 countries in North America, Central and South America, Europe, and the Asia Pacific region. For more information, visit Equifax.ca.

About Credit Canada
Credit Canada is a not-for-profit credit counselling agency providing free and confidential debt and credit counselling, personal debt management, debt consolidation and resolutions, as well as preventative counselling, educational seminars, and free tips and tools in the areas of budgeting, money management, and financial goal-setting. Credit Canada is Canada’s first and longest-standing credit counselling agency and a leader in financial wellness, helping Canadians successfully manage their debt since 1966. Please visit www.creditcanada.com for more information and follow us on Facebook and Twitter.

Media Contact:

Andrew Findlater
SELECT Public Relations
[email protected]
(647) 444-1197

Pandemic-driven demand for cloud may be stymied by migration challenges

iland research reveals hidden pitfalls of hyperscale cloud and low confidence in key features of cloud services, while a lack of resources is holding back cloud migration projects for 83%

HOUSTON, Nov. 12, 2020 (GLOBE NEWSWIRE) — iland, a leading VMware-based cloud services provider for application hosting, data protection and disaster recovery, today released the findings of its research into customer confidence in cloud services. It found that despite the increase in cloud adoption due to the pandemic, three quarters of organisations surveyed say hyperscaler IaaS instance types may not meet their cost and performance needs for mission-critical applications, while more than one in five are not satisfied with key features of cloud provision such as security, performance, availability and support.

The research also found that a lack of migration resources is delaying or preventing cloud projects for more than 80% of organisations surveyed.

The research: The Hidden Pitfalls of Working with Hyperscale Clouds was conducted among 501 senior IT executives, including CIOs, CISOs and CTOs, in the UK and US by independent research organisation, Opinion Matters, in June 2020. Participants were asked for their views on security, performance, compliance and their overall level of confidence in the cloud services they have invested in.

Key research findings include:

  • 83% say lack of migration resources and/or time has delayed cloud migration. Among those, 12% say it has entirely prevented migration.
  • 75% say a T Shirt size or hyperscaler instance type does not meet all their performance and cost requirements.
  • 24% are not confident that hyperscale clouds can meet performance and availability requirements for specific applications.
  • 23% are not confident that production data is protected via backup or disaster recovery in the event of data loss with their cloud service provider.
  • 24% are not confident they can get the support they need from their cloud service provider.
  • 53% say security is the top factor in cloud supplier selection.
  • 76% agree CSPs should assist or actively manage customer data compliance.

Commenting on the research findings, Researcher Charles Moore said: “While cloud adoption has seen a significant uptick due to the pandemic, the lack of migration resources for many customers has delayed or prevented deployment. Customers need to choose a cloud vendor that can fill the internal resource gaps that can hinder success.”

Justin Giardina, iland Chief Technology Officer, added: “The business benefits of moving to the cloud are indisputable, but with 83% of those surveyed saying that migration resources are necessary to achieve those benefits it’s clear that customers need to look beyond just the cloud platform and ensure their vendor can offer the supporting services that can reduce risk and improve time to value.”

“Hyperscale cloud services are missing the mark for a significant proportion of the organisations surveyed,” continues Giardina. “Having trust in critical cloud features is fundamental to realising its benefits, so with more than one in five respondents lacking confidence in aspects such as performance, availability, backup and support points to the hidden pitfalls of hyperscale clouds.”

Security, management, visibility, and control are priority customer requirements for cloud solutions

The study also found that key requirements for cloud service provision include common or unified management across all services; this is a priority for 73% of those adopting multi-cloud solutions. Similarly, infrastructure visibility and control are must-have features for 71% of respondents. Many were looking to the future, with 89% saying it was important or critical that they can write to their CSP’s API for future software development and deployment.

Security is a primary criterion for cloud provider selection, with 53% saying it is the leading consideration and a further 43% saying it is a major factor. Three quarters of customers also want to see cloud service providers helping manage data compliance.

The survey found that the majority (74%) of respondents felt it was important that CSPs preserve their company’s existing networking environment when they move to the cloud. This reflects the current landscape, where many organisations are being forced to accelerate their cloud adoption programmes due to the pressures of supporting large-scale remote working. Giardina notes: “When organisations are being rapidly pushed out of their comfort zones and forced to shrink deployment schedules to the absolute minimum, being able to maintain the familiar networking environment in the cloud is an advantage that is appealing to under-pressure IT departments.”

Read the full iland research report here.

About iland

iland is a global cloud service provider of secure and compliant hosting for infrastructure (IaaS), disaster recovery (DRaaS), and backup as a service (BaaS). They are recognized by industry analysts as a leader in disaster recovery. The award-winning iland Secure Cloud Console natively combines deep layered security, predictive analytics, and compliance to deliver unmatched visibility and ease of management for all of iland’s cloud services. Headquartered in Houston, Texas and London, UK, iland delivers cloud services from its data centers throughout North America, Europe, Australia, and Asia. Learn more at www.iland.com.

James Costanzo
iland
6315535860
[email protected]

Ocuphire Pharma Announces Two Publications Supporting the APX3330 Program

Emerging data on the benefits of Ref-1 inhibition via APX3330 have shown its potential to treat multiple inflammatory and angiogenic disease processes

FARMINGTON HILLS, Mich., Nov. 12, 2020 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc., (Nasdaq: OCUP) a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, today announced the publication of two seminal papers supporting its APX3330 program. The first is a review paper on the Ref-1 protein, a novel molecular target involved in multiple inflammatory and angiogenic disease processes, focusing on ocular, gastrointestinal, and cancer disorders in Drug Discovery Today, a journal dedicated to all aspects of preclinical drug discovery. The second publication covers a preclinical study outlining the benefits of APX3330 that were shown in mouse models of chronic colitis, an inflammatory condition, in the peer-reviewed journal Inflammatory Bowel Disease.

The publication entitled, The multifunctional APE1 DNA repair–redox signaling protein as a drug target in human disease,” reported the following:

  • Ref-1 has emerged as a novel therapeutic target developed for treating ocular diseases
  • Findings in other indications, such as in preclinical models of cancer and IBD, support the targeting of Ref-1 to interfere with angiogenesis and inflammation in ocular disease such as diabetic retinopathy (DR), diabetic macular edema (DME), and age-related macular degeneration (AMD) with APX3330, APX2009, and APX2014
  • Findings from a solid tumor Phase-1 trial, where doses up to 600 mg per day of APX3330 demonstrated chronic tolerability, for some patients up to a year
  • Use of Ref-1 inhibitors has also promoted prevention of neuropathy in preclinical studies

The full online publication can be accessed at the following link: sciencedirect.com

The second publication entitled, Inhibition of APE1/Ref-1 Redox Signaling Alleviates Intestinal Dysfunction and Damage to Myenteric Neurons in a Mouse Model of Spontaneous Chronic Colitis,” reported the following:

  • Inflammation-induced oxidative stress is implicated in the pathophysiology of GI dysfunction in IBD
  • When given systemically to mice with chronic colitis, APX3330 reduced mitochondrial superoxide production, oxidative DNA damage, leading to neuroprotective effects of the enteric nervous system
  • APX3330 improved disease severity, reduced immune cell infiltration, restored GI function, and demonstrated Ref-1 target inhibition

The full online publication can be accessed at the following link: academic.oup.com

Mark Kelley, PhD, member of Ocuphire’s Ocular Medical Advisory Board, commented, “The results presented in both publications support the underlying mechanism of action of Ref-1 inhibitors in the prevention of inflammation and angiogenesis as well as the potential chronic daily use of APX3330 for ocular diseases.”

These publications offer evidence on the anti-inflammatory and anti-angiogenesis benefits of APX3330, and with the increasing implications of inflammatory pathways in diabetic eye disease, there is significant promise for its success in treating diabetic retinopathy, macular edema, and wet age-related macular degeneration.

APX
3330 to be Investigated in the
ZETA-1 Phase 2 Trial in Diabetic Retinopathy

The planned multi-center, randomized, placebo-controlled, double-masked Phase 2 study is designed to evaluate the efficacy of daily oral dosing of APX3330 to improve Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) score in patients with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) or mild proliferative diabetic retinopathy (PDR). The trial is expected to enroll 100 patients in early 2021 over multiple sites in the US and will evaluate a 600mg daily dosage of APX3330 over the course of 24 weeks. The primary endpoint will be the percentage of patients with a ≥ 2-step improvement in DRSS score in the study eye at week 24. Please refer to ocuphire.com for more information.

About Ocuphire Pharma

Ocuphire is a publicly traded (NASDAQ: OCUP), clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire’s pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications. The company’s lead product candidate, Nyxol® Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, and is being developed for several indications, including dim light or night vision disturbances, pharmacologically-induced mydriasis, and presbyopia. Ocuphire’s second product candidate, APX3330, is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema. As part of its strategy, Ocuphire will continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late stage development, regulatory preparation and commercialization of drugs in key global markets. Please visit www.clinicaltrials.gov to learn more about Ocuphire’s recent Phase 2 clinical trials. For more information, please visit www.ocuphire.com.


Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning Ocuphire’s product candidates and potential. These forward-looking statements are based upon Ocuphire’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of
various risks and uncertainties, including, without limitation: (i) the success and timing of regulatory submissions and pre-clinical and clinical trials; (ii) regulatory requirements or developments; (i
ii
) changes to clinical trial designs and regulatory pathways; (
i
v) changes in capital resource requirements; (v) risks related to the inability of Ocuphire to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs; (vi) legislative, regulatory, political and economic developments, and (vii) the effects of COVID-19 on clinical programs and business operations. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors detailed in documents that have been and may be filed by Ocuphire from time to time with the SEC (including the proxy statement/prospectus included in that certain Registration Statement on Form S-4 (File No. 333-239702) initially filed with the SEC on July 6, 2020 and declared effective by the SEC on October 2, 2020. All forward-looking statements contained in this press release speak only as of the date on which they were made. Ocuphire undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Ocuphire Contact:

Mina Sooch, President & CEO
Ocuphire Pharma, Inc.
(248) 681-9815
[email protected]
www.ocuphire.com

Corey Davis, Ph.D.
LifeSci Advisors
[email protected]

Inozyme Pharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights

–  Submitted CTA for INZ-701 for the treatment of ENPP1 deficiency to United Kingdom regulatory agency –

–  Received Rare Pediatric Disease and Fast Track Designations for INZ-701 for the treatment of ENPP1 deficiency –

–  Expect to initiate INZ-701 Phase 1/2 clinical trials for ENPP1 and ABCC6 deficiencies in first half of 2021 –

BOSTON, Nov. 12, 2020 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton, today reported financial results for the third quarter ended September 30, 2020 and provided recent business highlights.

“ENPP1 deficiency is a systemic, progressive and continuous disease occurring over the course of a patient’s lifetime, starting as early as fetal development and spanning into adulthood. The fact that INZ-701 had previously received orphan drug designation and now rare pediatric disease and fast track designations underscores the significant unmet medical need for a treatment for this disease,” said Axel Bolte, MSc, MBA, co-founder, president and chief executive officer of Inozyme Pharma. “I’m pleased with the progress we have made with U.S. and European regulatory authorities, and we remain on track to initiate our planned Phase 1/2 clinical trials in the first half of 2021, subject to clearance of our regulatory applications.”

Recent Business Highlights

  • Submitted Clinical Trial Application (CTA) for INZ-701 for the treatment of ENPP1 deficiency – Inozyme recently submitted its first CTA to initiate a Phase 1/2 clinical trial of INZ-701 for the treatment of ENPP1 deficiency to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA).
  • Received Rare Pediatric Disease Designation and Fast Track Designation from the U.S. Food and Drug Administration (FDA) for INZ-701 for the treatment of ENPP1 deficiency – The FDA grants rare pediatric disease designation to drugs for serious and life-threatening diseases in which the serious or life-threatening manifestations primarily affect children aged from birth through 18 years and affect fewer than 200,000 people in the U.S. Under the FDA’s Rare Pediatric Disease Priority Review Voucher program, a sponsor who receives approval of a biologics license application (BLA) for a rare pediatric disease product application may be eligible for a voucher which can be redeemed to obtain priority review for a subsequent marketing application for a different product. Separately, Fast Track Designation facilitates the potential expedited development and review of a drug for the treatment of a serious or life-threatening disease and that has demonstrated the potential to address unmet medical needs. Benefits of this designation include frequent engagements with the FDA to discuss the drug’s clinical development plan, eligibility for priority review, and a rolling review of a BLA. Previously, the FDA and the European Medicines Agency (EMA) had granted orphan drug designation to INZ-701 for the treatment of ENPP1 deficiency.
  • Completed disease burden study in ENPP1 deficiency and ABCC6 deficiency – Inozyme and GACI Global, a patient advocacy organization dedicated to bettering the lives of families affected by Generalized Arterial Calcification of Infancy and/or Autosomal Recessive Hypophosphatemic Rickets Type 2 (GACI/ARHR2), completed a study to characterize the burden of disease and understand the systemic progression of disease for the rare genetic diseases of both ENPP1 deficiency and ABCC6 deficiency from the perspective of a patient and/or parent. Inozyme expects to share data from this study in 2021.

Upcoming Anticipated Milestones, Subject to COVID-19 Dynamics

  • INZ-701 for ENPP1 deficiency

    • Early 2021: Clearance of IND and CTAs
    • H1 2021: Initiation of Phase 1/2 clinical trial
    • H1 2021: Initiation of prospective natural history study
    • H2 2021: Preliminary safety and biomarker data from Phase 1/2 clinical trial
  •  INZ-701 for ABCC6 deficiency

    • Early 2021: Clearance of CTAs
    • H1 2021: Initiation of Phase 1/2 clinical trial
    • H2 2021: Preliminary safety and biomarker data from Phase 1/2 clinical trial

Upcoming Investor Conference

  • Piper Sandler 32nd Annual Healthcare Conference, November 30 – December 3, 2020

Third Quarter 2020 Financial Results

  • Cash Position and Financial Guidance – Cash, cash equivalents and investments were $171.7 million as of September 30, 2020. Based on its current plans, the Company expects that its existing cash, cash equivalents and investments will be sufficient to enable it to fund its operating expenses and capital expenditure requirements at least into the second half of 2022.
  • Research and Development (R&D) Expenses– R&D expenses were $25.2 million for the third quarter ended September 30, 2020, compared to $3.3 million for the same period in 2019. The increase was primarily due to an increase of $17.8 million resulting from the non-recurring, non-cash purchase of in-process research and development intellectual property assets from Alexion in exchange for stock of the Company in July 2020, costs associated with preclinical studies and clinical preparation activities with the Company’s CRO, and growth in the number of R&D employees.
  • General and Administrative (G&A) Expenses – G&A expenses were $3.1 million for the third quarter ended September 30, 2020, compared to $1.0 million for the same period in 2019. The increase was primarily due to the growth in the number of G&A employees, an increase in legal fees related to patents, new contracts and operations as a public company, and generally higher fees in areas such as audit, tax and information technology to support the Company’s growth.
  • Net Loss – Net loss was $28.1 million, or $1.55 loss per share, for the third quarter ended September 30, 2020, compared to $4.0 million, or $3.38 loss per share, for the same period in 2019.

About Inozyme Pharma

Inozyme Pharma, Inc. (Nasdaq: INZY), is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. Through our in-depth understanding of the biological pathways involved in mineralization, we are pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. It is well established that two genes, ENPP1 and ABCC6, play key roles in a critical mineralization pathway and that defects in these genes lead to abnormal mineralization. We are initially focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies.

Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University. For more information, please visit www.inozyme.com.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the initiation and timing of our future clinical trials, our research and development programs, the availability of preclinical study and clinical trial data, the timing of our regulatory applications and the period over which we believe that our existing cash, cash equivalents and investments will be sufficient to fund our operating expenses. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the Company’s ability to successfully resolve the clinical hold with regard to its planned Phase 1/2 clinical trial of INZ-701 for ENPP1 deficiency; obtain and maintain necessary approvals from the FDA and other regulatory authorities; continue to advance its product candidates in preclinical studies and clinical trials; replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; advance the development of its product candidates under the timelines it anticipates in planned and future clinical trials; obtain, maintain and protect intellectual property rights related to its product candidates; manage expenses; and raise the substantial additional capital needed to achieve its business objectives. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties and other important factors, in the Company’s most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof and should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.

Condensed Consolidated Balance Sheet Data
(Unaudited)

(in thousands)

  September 30,

2020
  December 31,

2019
Cash, cash equivalents and investments $ 171,709     $ 47,132  
Total assets   178,993       47,944  
Total liabilities   11,077       3,236  
Convertible preferred stock         77,927  
Additional paid-in-capital   247,872       1,428  
Accumulated deficit   (79,958 )     (34,652 )
Total stockholders’ equity (deficit)   167,916       (33,219 )
       

Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)

(in thousands, except share and per share data)

  Three Months Ended September 30,   Nine Months Ended September 30,
  2020   2019   2020   2019
Operating expenses:              
Research and development $              25,174     $                3,317     $              39,457     $              10,941  
General and administrative     3,142         1,003         6,313         3,097  
Total operating expenses     28,316         4,320         45,770         14,038  
Loss from operations     (28,316 )       (4,320 )       (45,770 )       (14,038 )
Other income (expense):              
Interest income     64         288         306         892  
Other income (expense), net     157         (3 )       158         (34 )
Other income (expense), net     221         285         464         858  
Net loss $             (28,095 )   $               (4,035 )   $             (45,306 )   $             (13,180 )
Other comprehensive (loss) income:              
Unrealized (losses) gains on available-for-sale securities     (13 )       (2 )       (5 )       8  
Total other comprehensive (loss) income     (13 )       (2 )       (5 )       8  
Comprehensive loss $             (28,108 )   $               (4,037 )   $             (45,311 )   $             (13,172 )
Net loss attributable to common stockholders—basic and diluted $             (28,095 )   $               (4,035 )   $             (45,306 )   $             (13,180 )
Net loss per share attributable to common stockholders—basic and diluted $                 (1.55 )   $                 (3.38 )   $                 (6.57 )   $               (11.20 )
Weighted-average common shares outstanding—basic and diluted     18,101,496         1,195,309         6,893,745         1,176,769  
               

Investors:
Brian Luque, Director, Investor Relations
(951) 206-1200
[email protected]

Media:

Alex Van Rees, SmithSolve
(973) 442-1555 ext. 111
[email protected]